Trials / NCT04636853
CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
Completed Phase 3 Gene therapy
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Treatment
- Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa, Dry Age-related Macular Degeneration
- Ages
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Started
- 2020-12-23
- Main results expected
- 2021-12-01
- Results posted
- Not yet
- Record last updated
- 2023-01-11
What the study is testing
The study will provides the enrollment of patients with genetic retinal dystrophies with primary rod impairment and dry age-related macular degeneration (Geographic type) A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.
A complete morpho-functional ophthalmological evaluation will be performed in all patients at each control.
Where it runs
Italy (1)
- Alfonso Savastano, Rome